培美曲塞联合奥沙利铂治疗老年晚期肺腺癌的临床疗效及安全性评估

目的 评估培美曲塞联合奥沙利铂治疗老年晚期肺腺癌的临床疗效及安全性.方法 选择西宁市第二人民医院于2009年2月至2011年3月治疗的老年晚期肺腺癌患者91例,按照随机数字表法分为观察组和对照组,对照组45例采用吉西他滨联合奥沙利铂治疗,观察组46例采用培美曲塞联合奥沙利铂治疗,观察比较两组患者的治疗情况.结果 观察组的总有效率为69.6%,略高于对照组的62.2%,组间差异无统计学意义（u=0.6213,P＞0.05）;观察组不良反应的发生显著少于对照组（P＜0.05）;观察组的18个月生存率为91.3%,显著高于对照组的75.6%（χ2=4.0983,P＜0.05）.结论 培美曲塞联合奥沙利铂治疗老年晚期肺腺癌的临床疗效满意,在安全性方面有明显优势,是临床首选的药物治疗方案.

Evaluation of Efficacy and Safety of Pemetrexed Combined with Oxaliplatin in the Treatment of Elderly Patients with Advanced Lung Adenocarcinoma

Objective To observe the efficacy and safety of pemetrexed combined with oxalipiatin in the treatment of elderly patients with advanced lung adenocarcinoma. Methods From February 2009 to March 2011 in Xining Second People＇s Hospital, 91 elderly patients with advanced lung adenocarcinoma were selected and randomly divided into two groups according to random number table, the control group （ 45 cases） treated with gemcitabine and oxaliplatin, the observation group （46 cases ）treated with pemetrexed combined with oxaliplatin,and the treatment data of two groups were compared and analyzed. Results The total effective rate of observation group was 69.6%, slightly higher than 62.2% of the control group, the difference was not statistically significant（ u =0. 6213 ,P 〉0.05 ） ; the incidence of adverse reactions in the observation group was significantly less than that of the control group, the difference was statistically signifi- cant （ P 〈 0.05 ） ; the 18-month survival rate of the observation group was 91.3 %, significantly higher than 75.6% of the control group, the difference was statistically significant（ 2 = 4. 0983, P 〈 O. 05 ）. Conclusion Pemetrexed combined with oxaliplatin in the treatment of elderly patients with advanced lung adenocarci- noma has satisfactory clinical efficacy, with obvious advantages in terms of safety, which is the preferred clinical drug treatment program.